nach oben

Erschienen in:

17.04.2023 | Original Article

Uncovering the molecular landscape of meningiomas and the impact of perioperative steroids on patient survival

verfasst von: Jacek Furtak, Marcin Birski, Marek Bebyn, Paulina Śledzińska, Stanisław Krajewski, Tadeusz Szylberg, Kamil Krystkiewicz, Jakub Przybył, Karolina Zielińska, Krystyna Soszyńska, Anna Majdańska, Agata Ryfa, Joanna Bogusiewicz, Barbara Bojko, Marek Harat

Erschienen in: Acta Neurochirurgica | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

The current literature on meningioma reveals a gap in knowledge regarding the impact of genetic factors on patient survival. Furthermore, there is a lack of data on the relationship between the perioperative use of corticosteroids and patient survival in meningioma patients. Our study aims to overcome these gaps by investigating the correlation between genetic factors and overall survival and the effect of postoperative corticosteroids and other clinical characteristics on patient outcomes in meningioma patients.

Methods

A retrospective analysis of the medical records of 85 newly diagnosed meningioma patients treated from 2016 to 2017 with follow-up until December 2022 was performed.

Results

NF2 mutations occurred in 60% of tumors, AKT1 mutations in 8.2%, and TRAF7 mutations in 3.6%. Most tumors in the parasagittal region had the NF2 mutation. On the other hand, almost all tumors in the sphenoid ridge area did not have the NF2 mutation. AKT-1-mutated meningiomas had more frequent peritumoral edema. Patients who received steroids perioperatively had worse overall survival (OS) than those without steroids (p = 0.034). Moreover, preoperative peri-meningioma edema also was associated with worse OS (p < 0.003). Contrarily, NF2 mutations did not influence survival.

Conclusions

The combination of clinical, pathomorphological, and genetic data allows us to characterize the tumor better and assess its prognosis. Corticosteroids perioperatively and peri-meningioma edema were associated with shorter OS, according to our study. Glucocorticoids should be used judiciously for the shortest time required to achieve symptomatic relief.

Graphical Abstract

Abedalthagafi M, Bi WL, Aizer AA et al (2016) Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro-Oncol 18:649–655CrossRefPubMedPubMedCentral

Birzu C, Peyre M, Sahm F (2020) Molecular alterations in meningioma: prognostic and therapeutic perspectives. Curr Opin Oncol 32:613CrossRefPubMed

Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45(3):285–289. https://doi.org/10.1038/ng.2526

Clark VE, Erson-Omay EZ, Serin A et al (2013) Genomic analysis of Non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080CrossRefPubMedPubMedCentral

Dubinski D, Won S-Y, Gessler F et al (2018) Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma. J Neurooncol 137:503–510CrossRefPubMed

Fontaine B, Rouleau GA, Seizinger BR, Menon AG, Jewell AF, Martuza RL, Gusella JF (1991) Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma)a. Ann N Y Acad Sci 615:338–343CrossRefPubMed

Gill CM, Loewenstern J, Rutland JW et al (2021) Peritumoral edema correlates with mutational burden in meningiomas. Neuroradiology 63:73–80CrossRefPubMed

Kostopoulou ON, Mohammad A-A, Bartek J Jr, Winter J, Jung M, Stragliotto G, Söderberg-Nauclér C, Landázuri N (2018) Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance. Int J Cancer 142:1266–1276CrossRefPubMed

Lemée J-M, Corniola MV, Da Broi M, Schaller K, Meling TR (2019) Early postoperative complications in meningioma: predictive factors and impact on outcome. World Neurosurg 128:e851–e858CrossRefPubMed

10.

Lobato RD, Alday R, Gómez PA, Rivas JJ, Domínguez J, Cabrera A, Madero S, Ayerbe J (1996) Brain oedema in patients with intracranial meningioma. Correlation between clinical, radiological, and histological factors and the presence and intensity of oedema. Acta Neurochir (Wien) 138:485–493 (discussion 493-494)CrossRefPubMed

11.

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol noab106

12.

Luedi MM, Singh SK, Mosley JC, Hatami M, Gumin J, Sulman EP, Lang FF, Stueber F, Zinn PO, Colen RR (2017) A dexamethasone-regulated gene signature is prognostic for poor survival in glioblastoma patients. J Neurosurg Anesthesiol 29:46CrossRefPubMedPubMedCentral

13.

Lu VM, Goyal A, Vaughan LS, McDonald KL (2018) The impact of hyperglycemia on survival in glioblastoma: a systematic review and meta-analysis. Clin Neurol Neurosurg 170:165–169CrossRefPubMed

14.

Mathiesen T, Lindquist C, Kihlström L, Karlsson B (1996) Recurrence of cranial base meningiomas. Neurosurgery 39:2–7 (discussion 8-9)CrossRefPubMed

15.

Morin O, Chen WC, Nassiri F et al (2019) Integrated models incorporating radiologic and radiomic features predict meningioma grade, local failure, and overall survival. Neuro-Oncol Adv 1:vdz011CrossRef

16.

Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro-Oncol 21:v1–v100CrossRefPubMedPubMedCentral

17.

Okano A, Miyawaki S, Hongo H, Dofuku S, Teranishi Y, Mitsui J, Tanaka M, Shin M, Nakatomi H, Saito N (2021) Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. Sci Rep 11(1):6987. https://doi.org/10.1038/s41598-021-86298-9

18.

Petrelli F, De Stefani A, Ghidini A, Bruschieri L, Riboldi V, Dottorini L, Iaculli A, Zaniboni A, Trevisan F (2021) Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis. J Neurol 268:440–447CrossRefPubMed

19.

Pitter KL, Tamagno I, Alikhanyan K et al (2016) Corticosteroids compromise survival in glioblastoma. Brain 139:1458–1471CrossRefPubMedPubMedCentral

20.

Preusser M, Brastianos PK, Mawrin C (2018) Advances in meningioma genetics: novel therapeutic opportunities. Nat Rev Neurol 14:106–115CrossRefPubMed

21.

RosenkrantzHölmich E, PetringHasselager R, Tvilling Madsen M, Orhan A, Gögenur I (2020) Long-term outcomes after use of perioperative glucocorticoids in patients undergoing cancer surgery: a systematic review and meta-analysis. Cancers 12:76CrossRef

22.

Sun C, Dou Z, Wu J et al (2020) The preferred locations of meningioma according to different biological characteristics based on voxel-wise analysis. Front Oncol 10

23.

Teranishi Y, Okano A, Miyawaki S et al (2022) Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. Acta Neuropathol Commun 10:76CrossRefPubMedPubMedCentral

24.

Wang X, Gong Y, Wang D et al (2012) Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and EGFL6 overexpression in benign meningioma tissue and serum. PLOS ONE 7:e52707CrossRefPubMedPubMedCentral

25.

Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, Ramesh V, Gusella JF, Wiestler OD, von Deimling A (1995) Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146:827–832PubMedPubMedCentral

26.

Weller M, Roth P, Sahm F, Burghardt I, Schuknecht B, Rushing EJ, Regli L, Lindemann JP, von Deimling A (2017) Durable control of metastatic AKT1-mutant WHO grade 1 meningothelial meningioma by the AKT inhibitor, AZD5363. J Natl Cancer Inst 109:1–4CrossRefPubMed

27.

Williams EA, Santagata S, Wakimoto H et al (2020) Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun 8:171CrossRefPubMedPubMedCentral

28.

Yennurajalingam S, Bruera E (2007) Palliative management of fatigue at the close of life: “it feels like my body is just worn out.” JAMA 297:295–304CrossRefPubMed

29.

Youngblood MW, Duran D, Montejo JD et al (2019) Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg 133:1345–1354CrossRef

Titel: Uncovering the molecular landscape of meningiomas and the impact of perioperative steroids on patient survival
verfasst von: Jacek Furtak
Marcin Birski
Marek Bebyn
Paulina Śledzińska
Stanisław Krajewski
Tadeusz Szylberg
Kamil Krystkiewicz
Jakub Przybył
Karolina Zielińska
Krystyna Soszyńska
Anna Majdańska
Agata Ryfa
Joanna Bogusiewicz
Barbara Bojko
Marek Harat
Publikationsdatum: 17.04.2023
Verlag: Springer Vienna
Erschienen in: Acta Neurochirurgica / Ausgabe 7/2023
Print ISSN: 0001-6268
Elektronische ISSN: 0942-0940
DOI: https://doi.org/10.1007/s00701-023-05567-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Uncovering the molecular landscape of meningiomas and the impact of perioperative steroids on patient survival